Its pipeline excluding CF consists of two parts: The first is investigational small molecule medicines in other serious diseases covering the areas of pain, protein deficiency and kidney diseases. The other is genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, muscular dystrophy and type-1 diabetes.
Specialist in cystic fibrosis medication plans to raise growth potential with expanding portfolio
Nasdaq-listed Vertex Pharmaceuticals is a global biotechnology company that innovates and creates transformative medicines for people with serious diseases. The company’s area of expertise lies in cystic fibrosis (CF), a rare life-threatening genetic disease, of which Vertex has multiple approved medicines along with several ongoing clinical and research programmes. Vertex derives all of its revenue from the CF segment as the rest of its research are only in the pipeline — either in Phase 2 or prior.
